A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2010
At a glance
- Drugs Moxifloxacin; Telaprevir
- Indications Bacterial infections; Hepatitis C
- Focus Pharmacodynamics
- Sponsors Janssen R&D Ireland
- 02 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Sep 2009 Actual initiation date (Sep 2009) added as reported by ClinicalTrials.gov.
- 30 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.